You are here

Publications

Found 11 results
Author Title Type [ Year(Asc)]
Filters: Author is Yasmeen, Anila  [Clear All Filters]
2025
Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K et al..  2025.  Precise targeting of HIV broadly neutralizing antibody precursors in humans.. Science. 389(6759):eadv5572.
2024
Caniels TG, Medina-Ramírez M, Zhang S, Kratochvil S, Xian Y, Koo J-H, Derking R, Samsel J, van Schooten J, Pecetta S et al..  2024.  Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.. Sci Immunol. 9(98):eadk9550.
Nelson AN, Shen X, Vekatayogi S, Zhang S, Ozorowski G, Dennis M, Sewall LM, Milligan E, Davis D, Cross KA et al..  2024.  Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.. Sci Immunol. 9(98):eadm7097.
2023
Colin P, Ringe RP, Yasmeen A, Ozorowski G, Ketas TJ, Lee W-H, Ward AB, Moore JP, Klasse PJ.  2023.  Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.. Retrovirology. 20(1):9.
Caniels TG, Medina-Ramírez M, Zhang J, Sarkar A, Kumar S, LaBranche A, Derking R, Allen JD, Snitselaar JL, Capella-Pujol J et al..  2023.  Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.. Cell Rep Med. 4(4):101003.
Ringe RP, Colin P, Ozorowski G, Allen JD, Yasmeen A, Seabright GE, Lee JHyun, Antanasijevic A, Rantalainen K, Ketas T et al..  2023.  Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.. PLoS Pathog. 19(10):e1011601.
2021
Ketas TJ, Chaturbhuj D, Portillo VMCruz, Francomano E, Golden E, Chandrasekhar S, Debnath G, Díaz-Tapia R, Yasmeen A, Kramer KD et al..  2021.  Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.. Pathog Immun. 6(1):116-134.
Derking R, Allen JD, Cottrell CA, Sliepen K, Seabright GE, Lee W-H, Aldon Y, Rantalainen K, Antanasijevic A, Copps J et al..  2021.  Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike.. Cell Rep. 35(1):108933.
Brouwer PJM, Antanasijevic A, de Gast M, Allen JD, Bijl TPL, Yasmeen A, Ravichandran R, Burger JA, Ozorowski G, Torres JL et al..  2021.  Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.. NPJ Vaccines. 6(1):24.
2018
Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens A-J, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E et al..  2018.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.. Biotechnol Bioeng. 115(4):885-899.
2015
Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW et al..  2015.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.. J Virol. 89(23):12189-210.